OncoCyte Corporation – Consensus Indicates Potential 108.4% Upside

Broker Ratings

OncoCyte Corporation found using ticker (OCX) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 11 and 7 and has a mean target at 8.67. Given that the stocks previous close was at 4.16 this is indicating there is a potential upside of 108.4%. There is a 50 day moving average of 4.73 and the 200 day moving average is 4.93. The company has a market cap of $388m. You can visit the company’s website by visiting: http://oncocyte.com

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics The company was founded in 2009 and is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  OncoCyte Corporation - Consensus Indicates Potential 155.0% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index